SCHEMBL6132332

SCHEMBL6132332

COC1(C2CCCCC2)CCC(=O)CC1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 6/20 0.33
PDE4B Q07343 6/20 0.33
PDE4C Q08493 6/20 0.33
PDE4D Q08499 6/20 0.33
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33
HSD11B1 P28845 1/20 0.33
KMT2A Q03164 1/20 0.32
ALDH1A1 P00352 4/20 0.32
TRIM24 O15164 1/20 0.32
TRIM33 Q9UPN9 1/20 0.32
APP P05067 1/20 0.31
BACE1 P56817 1/20 0.31
BACE2 Q9Y5Z0 1/20 0.31
CYP3A4 P08684 2/20 0.31
THRB P10828 1/20 0.31
MAPK1 P28482 1/20 0.31
CYP19A1 P11511 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6132212 0.98 LMNA (0.34) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL6132794 0.88 ALDH1A1 (0.35) HSD11B1ALDH1A1CYP3A4THRBMAPK1
SCHEMBL7741566 0.79 HSD11B1 (0.34) LMNATSHRHSD11B1KMT2ACYP3A4
SCHEMBL12389943 0.79 HSD11B1 (0.34) LMNATSHRHSD11B1KMT2ACYP3A4
SCHEMBL7732828 0.79 HSD11B1 (0.34) LMNATSHRHSD11B1KMT2ACYP3A4
SCHEMBL7739338 0.79 HSD11B1 (0.34) LMNATSHRHSD11B1KMT2ACYP3A4
SCHEMBL7738780 0.79 HSD11B1 (0.34) LMNATSHRHSD11B1KMT2ACYP3A4
SCHEMBL7733474 0.79 HSD11B1 (0.34) LMNATSHRHSD11B1KMT2ACYP3A4
SCHEMBL7739168 0.79 HSD11B1 (0.34) LMNATSHRHSD11B1KMT2ACYP3A4
SCHEMBL7735455 0.77 HSD11B1 (0.35) HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6884774-B2 Cyclic hexapeptide derivatives FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-04-26 US disclosed
US-6884868-B1 Cyclic hexapeptides having antibiotic activity FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-04-26 US disclosed
EP-1259535-B1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-04-13 EP disclosed
US-20030083238-A1 Cyclic hexapeptide derivatives ASTELLAS PHARMA INC. (JP) 2003-05-01 US disclosed
EP-1259535-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-27 EP disclosed
WO-2001060846-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083238-A1 Cyclic hexapeptide derivatives NGLY1, ALG1, CHIT1 PDE4A 1347/4885PDE4B 1719/4885PDE4C 1408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.